Rowinsky, E. K., Cote, G. M., Demetri, G. D., Maki, R. G., George, S., Li, D., Mita, A. C., Mita, M. M., Ahnert, J. R., Lu, D., Liu, D., Huang, L., Tonra, J. (2026). First-in-human clinical evaluation of ST-01156, an optimized and selective degrader of RNA-binding motif 39 (RBM39): A phase 1 study in advanced solid malignancies with a focus on RBM39-dependent cancers.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps3164